Literature DB >> 1914533

Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.

P Hildebrandt1.   

Abstract

One major problem encountered when treating diabetic patients with insulin is the very large inter- and intra-individual variability in subcutaneous insulin absorption, a major contributory factor in the variability of the blood glucose level. Thus, to optimize insulin treatment the factors influencing the absorption have to be known and possibly utilized. The different types of insulin ("short-acting", "intermediate-acting" and "long-acting") have different times of action. "Short-acting" and "intermediate-acting" human insulin are probably absorbed slightly faster than porcine (and bovine) insulin. "Long-acting" human insulin is absorbed significantly faster than bovine insulin. More concentrated "short-acting" insulin (100 IU/ml) is absorbed slightly slower than less concentrated insulins (40 IU/ml). The absorption of "intermediate-acting" and "long-acting" insulin is dose-dependent, with a decreasing absorption rate with increasing dose of insulin. Insulin is administered subcutaneously either by injection or by using an infusion pump. The injection technique influences the absorption rate. Giving a continuous subcutaneous insulin infusion as a basal rate infusion, a depot is built-up. The building-up and the size of the depot, as well as the blood glucose and plasma insulin levels during steady-state conditions, are independent of the pulse-rate interval of the pump used (5 min vs 1 h). The size of the steady-state depot is constant during constant conditions but inversely correlated to the local subcutaneous blood flow and directly correlated to the infusion rate. An increase or decrease in the infusion rate during a basal rate infusion will after a delay of 2-3 h induce corresponding changes in the insulin absorption rate from the depot. After termination of the infusion, the insulin depot will still provide some insulin supply for 2-3 h. During the continuous infusion, the pharmacokinetics of the superimposed preprandial boluses will resemble injections of soluble insulin. The inter- and intra-individual variability in the insulin absorption, even when giving the same type, species, concentration and dose of insulin, is presumably primarily due to different and changing diffusion conditions in the subcutaneous tissue. Some factors which influence the diffusion conditions include exercise, local massage and, especially, local subcutaneous blood flow. Alterations in the blood flow induce, with a hyperbolic relationship, changes in the same direction in the absorption rate of injected and infused "short-acting" insulin and of injected "intermediate-acting" insulin. Several factors have been shown to influence both subcutaneous blood flow and insulin absorption, e.g. injection site, skinfold thickness, smoking, orthostatic changes, ketosis and ambient temperature.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914533

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  13 in total

1.  Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model.

Authors:  S A Charman; D N McLennan; G A Edwards; C J Porter
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence.

Authors:  Fang Wu; Suraj G Bhansali; Wing Cheung Law; Earl J Bergey; Paras N Prasad; Marilyn E Morris
Journal:  Pharm Res       Date:  2012-02-29       Impact factor: 4.200

3.  Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.

Authors:  S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

4.  Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

Authors:  Sabrina Lyngbye Wendt; Ajenthen Ranjan; Jan Kloppenborg Møller; Signe Schmidt; Carsten Boye Knudsen; Jens Juul Holst; Sten Madsbad; Henrik Madsen; Kirsten Nørgaard; John Bagterp Jørgensen
Journal:  J Diabetes Sci Technol       Date:  2017-02-01

5.  Long-term glycemic control and prevention of diabetes complications in vivo using oleic acid-grafted-chitosan‑zinc-insulin complexes incorporated in thermosensitive copolymer.

Authors:  Divya Sharma; Jagdish Singh
Journal:  J Control Release       Date:  2020-04-10       Impact factor: 9.776

6.  Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes.

Authors:  Klaus Rave; Tim Heise; Lutz Heinemann; Anders H Boss
Journal:  J Diabetes Sci Technol       Date:  2008-03

7.  A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: model structure and parameter identification.

Authors:  Jason Wong; J Geoffrey Chase; Christopher E Hann; Geoffrey M Shaw; Thomas F Lotz; Jessica Lin; Aaron J Le Compte
Journal:  J Diabetes Sci Technol       Date:  2008-07

8.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

Authors:  P Kurtzhals; S Havelund; I Jonassen; B Kiehr; U D Larsen; U Ribel; J Markussen
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

10.  Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects.

Authors:  G Sindelka; L Heinemann; M Berger; W Frenck; E Chantelau
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.